Skip to main content.
kumc.edu
Home

Chao H. Huang, MD FACP

Chao Huang portrait
Associate Professor, Medical Oncology

Clinical Professor, Medical Oncology

chuang2@kumc.edu

Professional Background

I precept and teach medical students, residents and fellows in the field of clinical hematology and medical oncology, with a focus on diagnosis, work up and clinical management, preferring clinical trials. I have a special interest in the field of lung cancer and head and neck cancer, especially in multimodality therapy combining radiation with chemotherapy and immunotherapy.

Education and Training
  • University Preparatory Studies, Colegio Rosario , Porto Alegre, Rio Grande do Sul
  • MD, Medical Doctor , Univ. Fed. de Rio Grande do Sul, Porto Alegre , Rio Grande do Sul
  • Internship, Internal Medicine, Presbyterian Medical Center of Univ of Pennsylvania Health, Philadelphia, , PA
  • Residency, Internal Medicine , Presbyterian Medical Center University of Pennsylvania Health System, Philadelphia,, PA
  • Presbyterian Medical Center University of Pennsylvania Health System , Philadelphia, PA
  • Clinical Fellowship, Hematology & Medical Oncology , Fox Chase Cancer Center and Temple University Hospital
  • Other, Fox Chase Cancer Center and Temple University Hospital
Licensure, Accreditations & Certifications
  • Hematology , American Board of Hematology
  • Internal Medicine , American Board Of Internal Medicine
  • Kansas License , Kansas
  • Medical Oncology , American Board of Medical Oncology
  • Pennsylvania, Pennsylvania
Professional Affiliations
  • Member American Society of Hematology, Member, 2003 - Present
  • Southwest Oncology Group, Member, 2003 - Present
  • American Society of Clinical Oncology, Member, 1999 - Present
  • Member American Association for Cancer Research , Member, 1998 - Present
  • American College of Physicians, Member, 1994 - Present
Current Research and Grants
  • S1800A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) versues Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (lung-MAP Non-matched Sub-Study), SWOG-NCI, PI
  • Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC), Alliance for Clinical Trials in Oncology, PI
  • Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers, ECOG, PI
  • A Phase 3, Controlled, Open-label Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma, EpicentRx, PI
  • A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma, Trizell, PI
Publications
  • Islam, K.M., Deviany, Poppy., E., Anggondowati, Trisari, Ryan, June., E., Fetrick, Ann, Bagenda, Danstan, Copur, Mehmet., S., Tolentino, Addison, Vaziri, Irfan, McKean, Heidi., A., Dunder, Steven, Gray, Jhanelle., E., Huang, Chao., M.D., Ganti, Apar., Kishor. 2019. Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer. Journal of Oncology Practice, 15 (9), e758-e768. http://dx.doi.org/10.1200/jop.18.00734
  • Huang, Chao., H. 2019. Lung Cancer: Lung Cancer Regional Snapshot Kansas City VA Medical Center. Federal Practitioner
  • 2018. Randomized Phase 2 Study of Tivantinib Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer. Lung Cancer (117), 44-49
  • Park, John, McPike, Veronica, Kambhampati, Suman, Huang, Chao, Fields-Meehan, January, Verkruyse, Linda, Allen, Ace , Reddy, Eashwer. 2018. Positivity Rates in Oropharyngeal and Nonoropharyngeal Head and Neck Cancer in the VA. Fed Pract.. https://www.mdedge.com/fedprac/avaho/article/166785/head-neck-cancers/positivity-rates-oropharyngeal-and-nonoropharyngeal
  • Komiya, Takefumi, Huang, Chao., H. 2018. Updates in the Clinical Development of Epacadostat and Other Indoleamine 2, 3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. Frontier Oncology. https://doi.org/10.3389/fonc.2018.00423
  • Gerber, David., E, Socinski, Mark., A, Neal, Joel., W, Wakelee, Heather., A, Shirai, Keisuke, Sequist, Lecia., V, Rosovsky et al., Rachel., P. 2018. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung Cancer, 117, 44-49
  • Weng, Fen, Sood, Sumit, Yap, Wendall, Madan, Rashna, TenNapel, Mindi, Shen, Xinglei, Huang, Chao., H, Chen, Allen. 2018. Early-Stage Lung Adenocarcinoma treated with Stereotactic Body Radiation Therapy (SBRT)
  • Haque, Inamul, Motes, Hannah, Sharma, Mukut, Borrego, Emma, Reyes, Diaz, Godwin, Andrew., K, Huang, Chao ., H. 2018. - Modulation of microRNA expression in EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cell lines. Proceedings of the American Association for Cancer Research Y Volume 59 Y April 2018